Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Clinical Trial
Share your love
AGTC-501 Offers Vision Gains for X-Linked RP
Inherited retinal diseases (IRDs), also referred to as inherited retinal dystrophies, are a clinically and genetically heterogeneous group of neurodegenerative disorders, primarily involving photoreceptors, retinal pigment epithelium (RPE), and/or the choroid. Taken as a whole, IRDs have an estimated global…
FDA Approves Cyclosporine Eye Drops
Verkazia 0.1%) eye drops containing cyclosporine have been authorized by the US Food and Drug Administration (FDA) for the treatment of vernal keratoconjunctivitis (VKC) in both adult and juvenile populations. The surface of the eyes in patients with the uncommon,…
Improved Vision Through A Supplement
Mexican marigold also known as cempasúchil, or Aztec marigold is a native flower to México and was first used by the Aztecs and is used in the Mexican holiday “Dia de los muertos” or day of the dead. The Aztecs used it…
Oral Azithromycin vs Doxycycline for MGD
A study published online in JAMA Ophthalmology found that treatment of severe meibomian gland dysfunction (MGD) with three weeks of oral azithromycin is equivalent to six weeks of doxycycline. The study was conducted by Phit Upaphong, M.D., from Chiang Mai…
Ocumension Submits NDA for Zerviate in China
Nicox SA announced that its exclusive Chinese partner, Ocumension Therapeutics, has submitted a new drug application (NDA) seeking approval for commercialization of Zerviate (cetirizine ophthalmic solution), 0.24%, in China. The intended use of Zerviate is for the treatment of ocular…
Tepezza Improves Proptosis in Patients With Chronic TED
Horizon Therapeutics has announced positive and statistically significant topline results from its randomized, double-masked, placebo-controlled Phase 4 clinical trial evaluating TEPEZZA for the treatment of adults with chronic thyroid eye disease (TED) and low CAS, a measure of disease activity.…
Ultomiris Poised for EU Approval as NMOSD Treatment
AstraZeneca’s Ultomiris (ravulizumab) has received a recommendation for marketing authorization in the European Union (EU) for the treatment of adult patients who are anti-aquaporin-4 (AQP4) antibody positive (Ab+) and have neuromyelitis optica spectrum disorder (NMOSD). If authorized, Ultomiris would become…
Positive Results for Dry AMD Treatment by LumiThera
LumiThera announced the 24-month data from its LIGHTSITE III multicenter clinical trial. The results showed sustained vision improvement in subjects with dry age-related macular degeneration (AMD) who were treated with the Valeda Light Delivery System. LumiThera conducted LIGHTSITE III, a…
Updates On Central Serous Chorioretinopathy
Central serous chorioretinopathy, commonly referred to as CSC, is a condition in which fluid accumulates under the retina, causing a serous (fluid-filled) detachment and vision loss. CSC most often occurs in young and middle-aged adults. For unknown reasons, men develop…
Selagine and Grifols Team Up for DED Eye Drops
Selagine announced a global collaboration with Grifols to develop and commercialize immunoglobulin eye drops for dry eye disease. Financial terms of the agreement were not disclosed. As per the agreement, Selagine will receive an upfront payment and annual collaboration fee,…